18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of suspected paraneoplastic syndromes: A retrospective analysis

Paraneoplastic syndromes are a rare clinical presentation of tumor thought to affect 0.01% of patients with cancer. Paraneoplastic syndromes present a diagnostic challenge as a wide variety of signs and symptoms may appear. This study examines the use of18F-fluorodeoxyglucose positron emission tomog...

Full description

Bibliographic Details
Main Authors: Richard Bresler, William Schroeder Harry, David Z Chow, Ruth Lim
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:World Journal of Nuclear Medicine
Subjects:
Online Access:http://www.wjnm.org/article.asp?issn=1450-1147;year=2020;volume=19;issue=2;spage=124;epage=130;aulast=Bresler
id doaj-2079decd65c644cf89d118833662e581
record_format Article
spelling doaj-2079decd65c644cf89d118833662e5812020-11-25T03:24:23ZengWolters Kluwer Medknow PublicationsWorld Journal of Nuclear Medicine1450-11471607-33122020-01-0119212413010.4103/wjnm.WJNM_48_1918F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of suspected paraneoplastic syndromes: A retrospective analysisRichard BreslerWilliam Schroeder HarryDavid Z ChowRuth LimParaneoplastic syndromes are a rare clinical presentation of tumor thought to affect 0.01% of patients with cancer. Paraneoplastic syndromes present a diagnostic challenge as a wide variety of signs and symptoms may appear. This study examines the use of18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) as a diagnostic imaging tool for detecting tumor in suspected paraneoplastic syndrome cases. This single-center retrospective study included patients with suspected paraneoplastic syndrome who underwent whole-body18F-FDG PET/CT scan between December 2005 and December 2016. Associated clinical data were gathered via electronic chart review. Patient records were reviewed for age, sex, clinical signs and symptoms, ancillary diagnostic procedures, date of diagnosis, and follow-up time. Ninety-nine patients met inclusion criteria for this study. Mean follow-up period was 1.8 years. Cancer prevalence was 12.1%. The18F-FDG PET/CT results are as follows: 10 true positives, 5 false positives, 82 true negatives, and 2 false negatives. The diagnostic values are as follows: sensitivity 83.3%, specificity 94.3%, positive predictive value 66.7%, and negative predictive value (NPV) 97.6%. The high NPV in our study supports the effectiveness of18F-FDG PET/CT to rule out tumor in suspected paraneoplastic syndrome. Future research aims to analyze which patients with suspected paraneoplastic syndrome would benefit most from18F-FDG PET/CT.http://www.wjnm.org/article.asp?issn=1450-1147;year=2020;volume=19;issue=2;spage=124;epage=130;aulast=Bresleroncologyparaneoplastic syndromepositron emission tomography/computed tomography
collection DOAJ
language English
format Article
sources DOAJ
author Richard Bresler
William Schroeder Harry
David Z Chow
Ruth Lim
spellingShingle Richard Bresler
William Schroeder Harry
David Z Chow
Ruth Lim
18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of suspected paraneoplastic syndromes: A retrospective analysis
World Journal of Nuclear Medicine
oncology
paraneoplastic syndrome
positron emission tomography/computed tomography
author_facet Richard Bresler
William Schroeder Harry
David Z Chow
Ruth Lim
author_sort Richard Bresler
title 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of suspected paraneoplastic syndromes: A retrospective analysis
title_short 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of suspected paraneoplastic syndromes: A retrospective analysis
title_full 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of suspected paraneoplastic syndromes: A retrospective analysis
title_fullStr 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of suspected paraneoplastic syndromes: A retrospective analysis
title_full_unstemmed 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of suspected paraneoplastic syndromes: A retrospective analysis
title_sort 18f-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of suspected paraneoplastic syndromes: a retrospective analysis
publisher Wolters Kluwer Medknow Publications
series World Journal of Nuclear Medicine
issn 1450-1147
1607-3312
publishDate 2020-01-01
description Paraneoplastic syndromes are a rare clinical presentation of tumor thought to affect 0.01% of patients with cancer. Paraneoplastic syndromes present a diagnostic challenge as a wide variety of signs and symptoms may appear. This study examines the use of18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) as a diagnostic imaging tool for detecting tumor in suspected paraneoplastic syndrome cases. This single-center retrospective study included patients with suspected paraneoplastic syndrome who underwent whole-body18F-FDG PET/CT scan between December 2005 and December 2016. Associated clinical data were gathered via electronic chart review. Patient records were reviewed for age, sex, clinical signs and symptoms, ancillary diagnostic procedures, date of diagnosis, and follow-up time. Ninety-nine patients met inclusion criteria for this study. Mean follow-up period was 1.8 years. Cancer prevalence was 12.1%. The18F-FDG PET/CT results are as follows: 10 true positives, 5 false positives, 82 true negatives, and 2 false negatives. The diagnostic values are as follows: sensitivity 83.3%, specificity 94.3%, positive predictive value 66.7%, and negative predictive value (NPV) 97.6%. The high NPV in our study supports the effectiveness of18F-FDG PET/CT to rule out tumor in suspected paraneoplastic syndrome. Future research aims to analyze which patients with suspected paraneoplastic syndrome would benefit most from18F-FDG PET/CT.
topic oncology
paraneoplastic syndrome
positron emission tomography/computed tomography
url http://www.wjnm.org/article.asp?issn=1450-1147;year=2020;volume=19;issue=2;spage=124;epage=130;aulast=Bresler
work_keys_str_mv AT richardbresler 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyinthediagnosisofsuspectedparaneoplasticsyndromesaretrospectiveanalysis
AT williamschroederharry 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyinthediagnosisofsuspectedparaneoplasticsyndromesaretrospectiveanalysis
AT davidzchow 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyinthediagnosisofsuspectedparaneoplasticsyndromesaretrospectiveanalysis
AT ruthlim 18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyinthediagnosisofsuspectedparaneoplasticsyndromesaretrospectiveanalysis
_version_ 1724601874616680448